TY - JOUR
T1 - Serial plasma catecholamine response early in the course of clinical acute myocardial infarction
T2 - Relationship to infarct extent and mortality
AU - Karlsberg, Ronald P.
AU - Cryer, Philip E.
AU - Roberts, Robert
N1 - Funding Information:
From the Divisions of Cardiology and Metabolism, School of Medicine. This work was supported in part by National Institutes of Health Grant HL 07081, SCOR Ischemic Heart Disease HL 17846, AM 20579 and RR 0036, and by Diabetic Children’s Welfare Association/American Diabetes Association, Greater St. Louis Affiliate. Received for publication Nov. 26, 1980; accepted Feb. 7, 1981. Reprint requests: Ronald P. Karl&erg, M.D., Cardiovascular Medical Group of Southern California, 414 North Camden Dr., Suite 800, Beverly Hills. CA 90210.
PY - 1981/7
Y1 - 1981/7
N2 - Clinical and experimental evidence suggest that sympathoadrenal activation contributes to mortality in patients with ischemic heart disease. To determine the level of sympathoadrenal activation in the very early phase of acute myocardial infarction (AMI) and to determine if location of infarction (anterior versus inferior) was related to sympathoadrenal activation, we studied norepinephrine (NE) and epinephrine (E) within 4 hours after the onset of symptoms and prior to any rise in plasma creatine kinase (CK). Mean (± SE) initial (NE = 591 ± 111 pg/ml and E = 73 ± 19 pg/ml), peak (NE = 1356 ± 178 and E ± 1098 ± 608) and average (NE = 815 ± 142 and E = 252 ± 68) plasma catecholamine concentrations were considerbly above normal (NE = 228 ± 10 and E = 34 ± 2 pg/ml, n 60) and values were similar for inferior and anterior infarctions. During an 18-month follow-up, three patients died in whom the AMI mean NE and E and peak CK were higher than in the eight late survivors. Thus the three AMI patients with peak EP values > 1000 died, whereas the eight AMI patients with peak EP values < 1000 survived (p < 0.01). The magnitude of sympathoadrenal activation early in the course of clinical AMI appeared related to the extent of myocardial damage and late mortality.
AB - Clinical and experimental evidence suggest that sympathoadrenal activation contributes to mortality in patients with ischemic heart disease. To determine the level of sympathoadrenal activation in the very early phase of acute myocardial infarction (AMI) and to determine if location of infarction (anterior versus inferior) was related to sympathoadrenal activation, we studied norepinephrine (NE) and epinephrine (E) within 4 hours after the onset of symptoms and prior to any rise in plasma creatine kinase (CK). Mean (± SE) initial (NE = 591 ± 111 pg/ml and E = 73 ± 19 pg/ml), peak (NE = 1356 ± 178 and E ± 1098 ± 608) and average (NE = 815 ± 142 and E = 252 ± 68) plasma catecholamine concentrations were considerbly above normal (NE = 228 ± 10 and E = 34 ± 2 pg/ml, n 60) and values were similar for inferior and anterior infarctions. During an 18-month follow-up, three patients died in whom the AMI mean NE and E and peak CK were higher than in the eight late survivors. Thus the three AMI patients with peak EP values > 1000 died, whereas the eight AMI patients with peak EP values < 1000 survived (p < 0.01). The magnitude of sympathoadrenal activation early in the course of clinical AMI appeared related to the extent of myocardial damage and late mortality.
UR - http://www.scopus.com/inward/record.url?scp=0019414580&partnerID=8YFLogxK
U2 - 10.1016/0002-8703(81)90408-7
DO - 10.1016/0002-8703(81)90408-7
M3 - Article
C2 - 7246410
AN - SCOPUS:0019414580
SN - 0002-8703
VL - 102
SP - 24
EP - 29
JO - American Heart Journal
JF - American Heart Journal
IS - 1
ER -